# Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

> **NCT06821503** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 72 (estimated)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** LM-108 injection
- **DRUG:** Penpulimab injection
- **DRUG:** Paclitaxel for injection (albumin bound)
- **DRUG:** Gemcitabine hydrochloride for injection

## Key facts

- **NCT ID:** NCT06821503
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-11
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06821503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06821503, "Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06821503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*